-
公开(公告)号:US09708286B2
公开(公告)日:2017-07-18
申请号:US14748925
申请日:2015-06-24
Applicant: LEO Laboratories Limited
Inventor: Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
IPC: C07C271/34 , C07D333/38 , C07C271/36 , C07C271/38 , C07D249/06 , C07D261/18 , C07D277/32 , C07D295/21 , C07D309/08 , C07D401/04 , C07D471/04 , C07D495/04 , C07D265/36 , C07D271/08 , C07D277/587 , C07D295/205 , C07D307/00 , C07D307/94 , C07D405/06 , C07D513/04 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07D209/42 , C07D217/26 , C07D231/14 , C07D231/56 , C07D237/28 , C07D249/04
CPC classification number: C07D261/18 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07C271/34 , C07C271/36 , C07C271/38 , C07C2603/86 , C07D209/08 , C07D209/42 , C07D213/79 , C07D215/50 , C07D217/26 , C07D231/14 , C07D231/56 , C07D233/90 , C07D237/28 , C07D239/28 , C07D249/04 , C07D249/06 , C07D261/20 , C07D263/34 , C07D265/36 , C07D271/08 , C07D277/32 , C07D277/56 , C07D277/587 , C07D295/182 , C07D295/205 , C07D295/21 , C07D307/00 , C07D307/68 , C07D307/94 , C07D309/08 , C07D333/38 , C07D333/40 , C07D401/04 , C07D405/06 , C07D471/04 , C07D493/08 , C07D495/04 , C07D513/04
Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.